BridgeBio Oncology Therapeutics, Inc. BBOT
2.56 USD +0.36 (+16.36%)
At closeNov 12, 2026, 4:05 AM EST
2.67 +0.11 +4.30%
Pre-market · Nov 12, 4:05 AM ET
2.25 Day range 2.65
1.98 52-week range 14.87
- YTD
- -79.55%
- 1 year
- -79.92%
News
benzinga.com These Analysts Cut Their Forecasts On BridgeBio Oncology After Q3 Results BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT) on Tuesday posted a narrower-than-expected loss for the third quarter.
benzinga.com These Analysts Cut Their Forecasts On BridgeBio Oncology After Q3 Results BridgeBio Oncology beat Q3 loss estimates, shares jumped 18%, while analysts cut price targets to $9 and $15.
benzinga.com Piper Sandler Maintains Overweight on BridgeBio Oncology, Lowers Price Target to $15 Piper Sandler analyst Biren Amin maintains BridgeBio Oncology (NASDAQ:BBOT) with a Overweight and lowers the price target from $21 to $15.
benzinga.com Wedbush Maintains Outperform on BridgeBio Oncology, Lowers Price Target to $9 Wedbush analyst David Nierengarten maintains BridgeBio Oncology (NASDAQ:BBOT) with a Outperform and lowers the price target from $25 to $9.- benzinga.com BridgeBio Oncology Q3 EPS $(0.43) Beats $(0.69) Estimate BridgeBio Oncology (NASDAQ:BBOT) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of $(0.69) by 37.68 percent. This is a 58.25 percent increase over losses of…
globenewswire.com BBOT Reports Third Quarter 2026 Financial Results and Update on Corporate Progress BBO-8520 plus pembrolizumab demonstrated a 75% ORR at 500 mg QD and 53% ORR across dose levels in 2L+ KRASG12C inhibitor-experienced NSCLC patients BBO-11818 and BBO-10203 combination cohorts…
benzinga.com Morgan Stanley Maintains Overweight on BridgeBio Oncology, Lowers Price Target to $13 Morgan Stanley analyst Sean Laaman maintains BridgeBio Oncology (NASDAQ:BBOT) with a Overweight and lowers the price target from $18 to $13.- benzinga.com Oppenheimer Maintains Outperform on BridgeBio Oncology, Lowers Price Target to $16 Oppenheimer analyst Mazahir Alimohamed maintains BridgeBio Oncology (NASDAQ:BBOT) with a Outperform and lowers the price target from $22 to $16.